CA2307850A1 - Use of macrolides for the treatment of cancer and macular degeneration - Google Patents

Use of macrolides for the treatment of cancer and macular degeneration Download PDF

Info

Publication number
CA2307850A1
CA2307850A1 CA002307850A CA2307850A CA2307850A1 CA 2307850 A1 CA2307850 A1 CA 2307850A1 CA 002307850 A CA002307850 A CA 002307850A CA 2307850 A CA2307850 A CA 2307850A CA 2307850 A1 CA2307850 A1 CA 2307850A1
Authority
CA
Canada
Prior art keywords
substituted
heteroaryl
aryl
previously defined
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002307850A
Other languages
English (en)
French (fr)
Inventor
Yat Sun Or
Jacob J. Plattner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2307850A1 publication Critical patent/CA2307850A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CA002307850A 1997-10-31 1998-10-30 Use of macrolides for the treatment of cancer and macular degeneration Abandoned CA2307850A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96147397A 1997-10-31 1997-10-31
US08/961,473 1997-10-31
PCT/US1998/023043 WO1999022722A2 (en) 1997-10-31 1998-10-30 Use of macrolides for the treatment of cancer and macular degeneration

Publications (1)

Publication Number Publication Date
CA2307850A1 true CA2307850A1 (en) 1999-05-14

Family

ID=25504514

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002307850A Abandoned CA2307850A1 (en) 1997-10-31 1998-10-30 Use of macrolides for the treatment of cancer and macular degeneration

Country Status (17)

Country Link
EP (1) EP1027060A2 (ko)
JP (1) JP2001521891A (ko)
KR (1) KR20010031577A (ko)
CN (1) CN1278178A (ko)
AR (1) AR043071A1 (ko)
AU (1) AU1206799A (ko)
BG (1) BG104436A (ko)
BR (1) BR9813318A (ko)
CA (1) CA2307850A1 (ko)
HU (1) HUP0100012A3 (ko)
IL (1) IL135518A0 (ko)
NO (1) NO20002189L (ko)
PL (1) PL340604A1 (ko)
SK (1) SK6172000A3 (ko)
TR (1) TR200001147T2 (ko)
WO (1) WO1999022722A2 (ko)
ZA (1) ZA989885B (ko)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5037771B2 (ja) 2000-04-13 2012-10-03 バイオチカ テクノロジー リミテッド グリコシル化されたハイブリッド産物およびその産生方法と利用
EP1539157B1 (en) 2002-09-18 2013-08-21 Trustees Of The University Of Pennsylvania Rapamycin for use in inhibiting or preventing choroidal neovascularization
US7091196B2 (en) 2002-09-26 2006-08-15 Rib-X Pharmaceuticals, Inc. Bifunctional heterocyclic compounds and methods of making and using same
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
CA2520732C (en) 2003-03-28 2012-12-04 Sloan-Kettering Institute For Cancer Research Migrastatin analogs and uses thereof
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
EP2716647A3 (en) 2004-02-27 2014-08-20 Rib-X Pharmaceuticals, Inc. Macrocyclic compounds and methods of making and using the same
CN1950388A (zh) * 2004-02-27 2007-04-18 瑞伯-X医药品有限公司 大环化合物以及其制作和使用方法
US8957056B2 (en) 2004-05-25 2015-02-17 Sloan-Kettering Instiute For Cancer Research Migrastatin analogs in the treatment of cancer
US8188141B2 (en) 2004-09-23 2012-05-29 Sloan-Kettering Institute For Cancer Research Isomigrastatin analogs in the treatment of cancer
BRPI0608152A2 (pt) 2005-02-09 2009-11-10 Macusight Inc formulações para tratamento ocular
CA2615990A1 (en) 2005-07-18 2007-01-25 Minu, L.L.C. Enhanced ocular neuroprotection/neurostimulation
US8470985B2 (en) 2005-08-24 2013-06-25 Rib-X Pharmaceuticals, Inc. Triazole compounds and methods of making and using the same
US8278281B2 (en) 2005-08-24 2012-10-02 Rib-X Pharmaceuticals, Inc. Triazole compounds and methods of making and using the same
CA2635797C (en) 2006-02-09 2015-03-31 Macusight, Inc. Stable formulations, and methods of their preparation and use
WO2007112052A2 (en) 2006-03-23 2007-10-04 Macusight, Inc. Formulations and methods for vascular permeability-related diseases or conditions
CN106317146B (zh) * 2015-06-18 2019-06-21 沈阳药科大学 双环克拉霉素衍生物及其作为肿瘤细胞增值抑制剂的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6461090A (en) * 1989-10-30 1991-05-02 Abbott Laboratories Injectable formulation for lipophilic drugs
US5498424A (en) * 1994-11-30 1996-03-12 Klein; Ira Method of treating obesity

Also Published As

Publication number Publication date
KR20010031577A (ko) 2001-04-16
JP2001521891A (ja) 2001-11-13
HUP0100012A2 (hu) 2001-05-28
CN1278178A (zh) 2000-12-27
BG104436A (en) 2000-12-29
WO1999022722A3 (en) 1999-08-05
HUP0100012A3 (en) 2003-07-28
EP1027060A2 (en) 2000-08-16
TR200001147T2 (tr) 2000-08-21
NO20002189L (no) 2000-06-28
ZA989885B (en) 1999-05-05
WO1999022722A2 (en) 1999-05-14
BR9813318A (pt) 2000-08-22
AR043071A1 (es) 2005-07-20
NO20002189D0 (no) 2000-04-27
IL135518A0 (en) 2001-05-20
SK6172000A3 (en) 2001-03-12
PL340604A1 (en) 2001-02-12
AU1206799A (en) 1999-05-24

Similar Documents

Publication Publication Date Title
CA2307850A1 (en) Use of macrolides for the treatment of cancer and macular degeneration
US5827895A (en) Hexahydrolupulones useful as anticancer agents
EP0869789B1 (en) Antiviral agent
JPH06263635A (ja) 抗腫瘍性を有する避妊および月経周期調節用薬剤、その使用方法とその製法
EP1025114B1 (en) 3'-n-modified 6-o-substituted erythromycin ketolide derivatives having antibacterial activity
HU211337A9 (en) 4"-deoxyerythromycin derivatives
CN1269803A (zh) 6,9－桥红霉素衍生物
SK13162001A3 (sk) 6-o-substituované makrolidy majúce antibakteriálnu aktivitu
CA2367319A1 (en) Erythromycin derivatives
MXPA97008611A (en) Compounds of dialquiltiacumic
CA2218916A1 (en) Dialkyltiacumicin compounds
US6946446B2 (en) Anti-infective agents useful against multidrug-resistant strains of bacteria
US6436906B1 (en) 9-amino-14-membered macrolides derived from leucomycins
JP2003507487A (ja) 抗菌活性を有する９ａ−アザライド類
CN113116859B (zh) 阿奇霉素丸芯包衣制剂
EP1259923B1 (en) Anti-infective agents useful against mulitidrug-resistant strains of bacteria
CZ20001524A3 (cs) Farmaceutický přípravek pro léčení nádorů a makulární degenerace
US6716820B1 (en) 6-O-substituted bicyclic macrolides
WO2002094183A2 (en) A method for tumor treatment with fumagillol derivatives
WO2023134707A1 (en) Methods for treating aml-mrc and mds
US5217960A (en) Erythromycin derivatives
WO2023195570A1 (ko) 슈퍼옥시드 디스무타아제를 포함하는 항암 조성물
US20040209827A1 (en) 11-C-substituted derivatives of clarithromycin
EP1258248A2 (en) Tumor treatments comprising a fumagillol derivative and a further antineoplastic agent
TWI229677B (en) 2-halo-6-O-substituted ketolide derivatives

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued